- Home
- STK vs PSNL Comparison
STK vs PSNL Comparison
Compare STK & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- PSNL
- Stock Information
- Founded
- STK 2009
- PSNL 2011
- Country
- STK United States
- PSNL United States
- Employees
- STK N/A
- PSNL N/A
- Industry
- STK Investment Managers
- PSNL Medical Specialities
- Sector
- STK Finance
- PSNL Health Care
- Exchange
- STK Nasdaq
- PSNL Nasdaq
- Market Cap
- STK 434.6M
- PSNL 460.7M
- IPO Year
- STK N/A
- PSNL 2019
- Fundamental
- Price
- STK $29.76
- PSNL $5.14
- Analyst Decision
- STK
- PSNL Strong Buy
- Analyst Count
- STK 0
- PSNL 5
- Target Price
- STK N/A
- PSNL $8.00
- AVG Volume (30 Days)
- STK 38.2K
- PSNL 756.3K
- Earning Date
- STK 01-01-0001
- PSNL 05-06-2025
- Dividend Yield
- STK 6.60%
- PSNL N/A
- EPS Growth
- STK N/A
- PSNL N/A
- EPS
- STK N/A
- PSNL N/A
- Revenue
- STK N/A
- PSNL $85,694,000.00
- Revenue This Year
- STK N/A
- PSNL N/A
- Revenue Next Year
- STK N/A
- PSNL $27.82
- P/E Ratio
- STK N/A
- PSNL N/A
- Revenue Growth
- STK N/A
- PSNL 15.57
- 52 Week Low
- STK $24.95
- PSNL $1.14
- 52 Week High
- STK $34.31
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- STK 67.66
- PSNL 71.42
- Support Level
- STK $27.85
- PSNL $3.98
- Resistance Level
- STK $28.75
- PSNL $5.39
- Average True Range (ATR)
- STK 0.50
- PSNL 0.36
- MACD
- STK 0.34
- PSNL 0.16
- Stochastic Oscillator
- STK 95.28
- PSNL 76.38
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.